Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women withRVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration: NCT01926028.
RCT Entities:
Background: Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods: This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results: The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration: NCT01926028.
Authors: Christina Lindgren; Mark I Neuman; Michael C Monuteaux; Kenneth D Mandl; Andrew M Fine Journal: Pediatrics Date: 2016-06-08 Impact factor: 7.124
Authors: Brad J Spellberg; Ashraf S Ibrahim; Valentina Avanesian; Yue Fu; Carter Myers; Quynh T Phan; Scott G Filler; Michael R Yeaman; John E Edwards Journal: J Infect Dis Date: 2006-06-06 Impact factor: 5.226
Authors: Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards Journal: Infect Immun Date: 2005-02 Impact factor: 3.441
Authors: Yue Fu; Ashraf S Ibrahim; Donald C Sheppard; Yee-Chun Chen; Samuel W French; Jim E Cutler; Scott G Filler; John E Edwards Journal: Mol Microbiol Date: 2002-04 Impact factor: 3.501
Authors: Ashraf S Ibrahim; Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Clint S Schmidt; John P Hennessey; Samuel W French; Michael R Yeaman; Scott G Filler; John E Edwards Journal: Vaccine Date: 2013-09-21 Impact factor: 3.641
Authors: Quynh T Phan; Carter L Myers; Yue Fu; Donald C Sheppard; Michael R Yeaman; William H Welch; Ashraf S Ibrahim; John E Edwards; Scott G Filler Journal: PLoS Biol Date: 2007-03 Impact factor: 8.029
Authors: Samuel Aballéa; Florent Guelfucci; Julian Wagner; Amine Khemiri; Jean-Paul Dietz; Jack Sobel; Mondher Toumi Journal: Health Qual Life Outcomes Date: 2013-10-11 Impact factor: 3.186
Authors: Christophe d'Enfert; Ann-Kristin Kaune; Leovigildo-Rey Alaban; Sayoni Chakraborty; Nathaniel Cole; Margot Delavy; Daria Kosmala; Benoît Marsaux; Ricardo Fróis-Martins; Moran Morelli; Diletta Rosati; Marisa Valentine; Zixuan Xie; Yoan Emritloll; Peter A Warn; Frédéric Bequet; Marie-Elisabeth Bougnoux; Stephanie Bornes; Mark S Gresnigt; Bernhard Hube; Ilse D Jacobsen; Mélanie Legrand; Salomé Leibundgut-Landmann; Chaysavanh Manichanh; Carol A Munro; Mihai G Netea; Karla Queiroz; Karine Roget; Vincent Thomas; Claudia Thoral; Pieter Van den Abbeele; Alan W Walker; Alistair J P Brown Journal: FEMS Microbiol Rev Date: 2021-05-05 Impact factor: 16.408
Authors: Kyla S Ost; Teresa R O'Meara; W Zac Stephens; Tyson Chiaro; Haoyang Zhou; Jourdan Penman; Rickesha Bell; Jason R Catanzaro; Deguang Song; Shakti Singh; Daniel H Call; Elizabeth Hwang-Wong; Kimberly E Hanson; John F Valentine; Kenneth A Christensen; Ryan M O'Connell; Brendan Cormack; Ashraf S Ibrahim; Noah W Palm; Suzanne M Noble; June L Round Journal: Nature Date: 2021-07-14 Impact factor: 49.962